Javascript must be enabled to continue!
Decreased Phenytoin Level During Antineoplastic Therapy: A Case Report
View through CrossRef
Summary: We report a case of interaction between anticonvulsant and antineoplastic drugs in one male patient with seizures from brain tumour. The patient was treated with phenytoin (PHT), phenobarbital (PB), and an antineoplastic protocol based on a combination regimen with carmustine (BCNU), vinblastin (VLB), methotrexate (MTX), and radiotherapy. Plasma concentrations of PHT fell from 9.4 to 5.6μg/ml 24 h after VLB administration, and remained low for at least 10 days. During this period, partial seizures occurred. Plasma concentrations of PB were unchanged during the period of observation. It is suggested that impaired absorption of PHT, caused by VLB or MTX or both, is responsible for this interaction.RESUMENSe describe un caso de interacción entre medicaciones anticonvulsivas y antineoplásicas en un enfermo con ataques debidos a un tumor cerebral. El paciente recibía un tratamiento con fenitoina (PHT), fenobarbital (PB) y un protocolo antineoplásico basado en una combinación de carmustina (BCNV), vinblastina (VLB), metrotexate (MTX) y radioterapia. Las concentraciones plasmáticas de PHT bajaron de 9.4 μ.g/ml a 5.6 μl/ml a las 24 horas de la administración de VLB y permanecieron bajas al menos durante 10 días. Durante este periódo se produjeron ataques parciales. Las concentraciones plasmáticas de PB no se modificaron durante este periodo. Se sugiere que una absorción alterada de la PHT causada por la VLB y/o el MTX es responsable de esta interacción.ZUSAMMENFASSUNGBericht über einen Fall einer Interaktion zwischen antikonvulsiver und antineoplastischer Therapie bei einem männlichen Patienten mit Anfällen bei einem Hirntumor. Der Patient wurde mit Phenytoin (PHT). Phenobarbital (PB) und einem antineoplastischen Protokoll behandelt, das in einer Kombination von Carmustin (BCNU), Vinblastin (VLB), Methotrexat (MTX) und Radiotherapie besteht. Die Plasmakonzen‐trationen des PHT Helen 24 Stunden nach VLB Verabfolgung von 9,4 μg/ml auf 5,6 μg/ml und blieben mindestens für 10 Tage niedrig. Während dieser Periode traten Partial‐anfälle auf. Die Plasmakonzentrationen des PB blieben während der Beobachtung unverändert. Es wird vermutet, daß eine beeinträchtigte absorption des PHT, hervorgerufen durch VLB und/oder MTX für diese Interaktion verantwortlich ist.
Title: Decreased Phenytoin Level During Antineoplastic Therapy: A Case Report
Description:
Summary: We report a case of interaction between anticonvulsant and antineoplastic drugs in one male patient with seizures from brain tumour.
The patient was treated with phenytoin (PHT), phenobarbital (PB), and an antineoplastic protocol based on a combination regimen with carmustine (BCNU), vinblastin (VLB), methotrexate (MTX), and radiotherapy.
Plasma concentrations of PHT fell from 9.
4 to 5.
6μg/ml 24 h after VLB administration, and remained low for at least 10 days.
During this period, partial seizures occurred.
Plasma concentrations of PB were unchanged during the period of observation.
It is suggested that impaired absorption of PHT, caused by VLB or MTX or both, is responsible for this interaction.
RESUMENSe describe un caso de interacción entre medicaciones anticonvulsivas y antineoplásicas en un enfermo con ataques debidos a un tumor cerebral.
El paciente recibía un tratamiento con fenitoina (PHT), fenobarbital (PB) y un protocolo antineoplásico basado en una combinación de carmustina (BCNV), vinblastina (VLB), metrotexate (MTX) y radioterapia.
Las concentraciones plasmáticas de PHT bajaron de 9.
4 μ.
g/ml a 5.
6 μl/ml a las 24 horas de la administración de VLB y permanecieron bajas al menos durante 10 días.
Durante este periódo se produjeron ataques parciales.
Las concentraciones plasmáticas de PB no se modificaron durante este periodo.
Se sugiere que una absorción alterada de la PHT causada por la VLB y/o el MTX es responsable de esta interacción.
ZUSAMMENFASSUNGBericht über einen Fall einer Interaktion zwischen antikonvulsiver und antineoplastischer Therapie bei einem männlichen Patienten mit Anfällen bei einem Hirntumor.
Der Patient wurde mit Phenytoin (PHT).
Phenobarbital (PB) und einem antineoplastischen Protokoll behandelt, das in einer Kombination von Carmustin (BCNU), Vinblastin (VLB), Methotrexat (MTX) und Radiotherapie besteht.
Die Plasmakonzen‐trationen des PHT Helen 24 Stunden nach VLB Verabfolgung von 9,4 μg/ml auf 5,6 μg/ml und blieben mindestens für 10 Tage niedrig.
Während dieser Periode traten Partial‐anfälle auf.
Die Plasmakonzentrationen des PB blieben während der Beobachtung unverändert.
Es wird vermutet, daß eine beeinträchtigte absorption des PHT, hervorgerufen durch VLB und/oder MTX für diese Interaktion verantwortlich ist.
Related Results
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Phenytoin Cream for the Treatment of Neuropathic Pain: Case Series
Phenytoin Cream for the Treatment of Neuropathic Pain: Case Series
BACKGROUND: Neuropathic pain can be disabling, and is often difficult to treat. Within a year, over half of all patients stop taking their prescribed neuropathic pain medication, w...
Interaction of Phenytoin and Folate in the Rat
Interaction of Phenytoin and Folate in the Rat
Summary: The interactions between folate and phenytoin were studied in the rat using a model in which constant, nontoxic, and continuously protective levels of phenytoin were main...
The Phenytoin Ataxia Enigma Unveiled “A Case Report’’
The Phenytoin Ataxia Enigma Unveiled “A Case Report’’
Background: Phenytoin (PHT) has been approved for the treatment of epilepsy. It belongs to the category of medications with a limited therapeutic window and requires therapeutic dr...
Chest Wall Hydatid Cysts: A Systematic Review
Chest Wall Hydatid Cysts: A Systematic Review
Abstract
Introduction
Given the rarity of chest wall hydatid disease, information on this condition is primarily drawn from case reports. Hence, this study systematically reviews t...
Single-Blind Placebo-Controlled Response Test with Phenytoin 10% Cream in Neuropathic Pain Patients
Single-Blind Placebo-Controlled Response Test with Phenytoin 10% Cream in Neuropathic Pain Patients
Background: Phenytoin cream applied topically has been explored in neuropathic pain conditions. In several case series, phenytoin 5% and 10% cream could reduce pain in a clinically...
Clinical Importance of Phenytoin Monitoring to Reduce Phenytoin-Related Toxicity in Saudi Patients with Epilepsy
Clinical Importance of Phenytoin Monitoring to Reduce Phenytoin-Related Toxicity in Saudi Patients with Epilepsy
Background: Phenytoin toxicity can result from overdose, dosage changes, drug interac-tions, or physiological alterations. Symptoms range from nausea and confusion to severe cases ...

